“INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION”. 2025. Editora Impacto Científico, October, 342-56. https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073.